Bank of America’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-35,500
Closed -$5.39M – 7797
2020
Q4
$5.39M Buy
+35,500
New +$4.66M ﹤0.01% 3063
2015
Q2
– Sell
-30,000
Closed -$5.17M – 7416
2015
Q1
$5.17M Buy
+30,000
New +$4.57M ﹤0.01% 2463
2014
Q4
– Sell
-200
Closed -$26K – 7983
2014
Q3
$26K Sell
200
-2,300
-92% -$237K ﹤0.01% 6905
2014
Q2
$221K Buy
+2,500
New +$240K ﹤0.01% 5463
2014
Q1
– Sell
-1,100
Closed -$124K – 8092
2013
Q4
$124K Sell
1,100
-100
-8% -$9.02K ﹤0.01% 5969
2013
Q3
$95K Sell
1,200
-300
-20% -$21.9K ﹤0.01% 6013
2013
Q2
$99K Buy
+1,500
New +$96.6K ﹤0.01% 6178

Other funds holding UTHR

Bank of America's UTHR Position: Q2 2026 in Review

Bank of America reduced its United Therapeutics (UTHR) stake by 10% in Q2 2026, selling an estimated $11.4M and leaving 179,235 shares worth $97.1M. The position accounts for 0.01% of the portfolio, ranked #1214.

Bank of America first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $118M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Bank of America held 179,235 shares of United Therapeutics worth $97.1M as of Q2 2026.
  • Bank of America sold 20,191 United Therapeutics shares in Q2 2026, an estimated $11.4M.
  • United Therapeutics made up 0.01% of Bank of America's portfolio in Q2 2026, its #1214 holding.
  • Bank of America first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Bank of America's United Therapeutics position peaked at $118M in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.